Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DPS-004
- Development stage
- Preclinical
- Lead developer
- Cellontech
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intradermal, Subcutaneous
01
Overview
DPS-004 is a preclinical-stage dermal filler candidate being developed by Cellontech for aesthetic indications, such as the correction of facial wrinkles and soft tissue augmentation. As part of Cellontech's specialized collagen technology platform, DPS-004 is designed to utilize highly purified atelocollagen to provide structural support and volume to the skin. The product functions by physically filling depressions in the dermal layer and providing a biocompatible scaffold that supports the integration of host tissues. Its development aims to offer a safe and long-lasting solution for skin rejuvenation by leveraging the regenerative properties of collagen.
Beyond the preview
Go deeper on DPS-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DPS-004.